Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

BCBiwei Cao

Discussion

Loading...

Member takes

Overview

Real-world experience shows accelerated glofitamab is feasible but indicates higher toxicity in high-risk DLBCL patients.

Key Points

  • To evaluate the feasibility and safety of accelerated dosing of glofitamab in high-risk relapsed/refractory DLBCL.
  • Single-center study of adults with R/R DLBCL receiving accelerated glofitamab.
  • Patients treated with obinutuzumab followed by step-up dosing of glofitamab over multiple cycles.
  • Safety and efficacy were monitored, including observation for cytokine release syndrome (CRS) and neurological adverse effects (ICANS).
  • 26 out of 29 planned patients received at least one dose of glofitamab.
  • Overall response rate (ORR) was 42%, with a complete response (CR) of 15%.
  • Cytokine release syndrome (CRS) occurred in 61% of patients, with grade 3 or higher CRS in 15%.
  • Median overall survival (OS) was 3.65 months and median progression-free survival (PFS) was 1.9 months.

Cite This Study

Biwei Cao (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d51chttps://doi.org/10.1182/blood-2025-5512
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  2. 2Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  3. 3Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  4. 4Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States2025
  5. 5Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.2025